IL6 and type 2 diabetes mellitus: Another major finding from our study was that HSVSMCs from T2DM patients produced significantly more mROS than those from the non-diabetic controls, and the degree of mROS inhibition by ruxolitinib with or without IL-6/sIL-6Rα or PDGF-BB stimulation was similar in cells from T2DM patients and controls (Figure 4).